Acasti Receives Full Data for Phase II TRIFECTA Trial By: Benzinga via Benzinga March 02, 2015 at 07:31 AM EST Acasti Pharma Inc. ("Acasti" or the "Corporation") (Nasdaq: ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the ... Read More >>